A failed trial is a failed trial, says China’s regulator
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
The NMPA has refused to back PFS, plus subgroup OS analyses, in fruquintinib’s stomach cancer study.
